Skye Bioscience, Inc. (SKYE)
NASDAQ: SKYE · Real-Time Price · USD
1.860
+0.080 (4.49%)
At close: Sep 4, 2026, 4:00 PM EDT
1.910
+0.050 (2.69%)
After-hours: Sep 4, 2026, 7:59 PM EDT

Skye Bioscience Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Income
-48.06-58.16-36.43-13.67-18.31-7.85
Net Income
-50.49-55.92-26.57-37.64-19.48-8.52
Earnings Per Share
-10.24-11.28-5.84-42.99-70.17-41.92
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
10.0625.7468.421.261.328.98
Total Debt
0.180.270.464.621.982.14
Net Cash (Debt)
9.8925.4667.96-3.36-0.666.85
Net Cash Growth
-79.50%-62.53%---604.71%
Net Cash Per Share
1.995.1414.90-3.84-2.3933.68

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-38.81-43.06-25.24-13.95-12.74-6.47
Capital Expenditures
--0.01-1.6-0.01-0.09-0.09
Free Cash Flow
-38.81-43.07-26.84-13.96-12.84-6.57
Free Cash Flow Growth
------

Valuation

Selected indicators aren't available for this stock.